28.01.2010 • Topics

Aramco, Sumitomo Award JGC Petrorabigh study deal

Saudi Aramco and Sumitomo have awarded Japan's JGC Corporation a contract for a feasibility study on the expansion of Rabigh Refining and Petrochemical (PetroRabigh). The study is expected to be completed by the third quarter of 2010, Aramco said. "Once the project is proven viable, Petrorabigh will be invited to decide on the implementation of the Rabigh II project," the company said. Petrorabigh, an export-oriented joint venture between state oil giant Aramco and Japan's Sumitomo Chemical, started partial operation of its facilities in the fourth quarter of 2008. Aramco and Sumitomo paired up in 2005 to upgrade the 400,000 bpd refinery and add a petrochemical complex, the largest in the region. In April Sumitomo said the two firms planned to expand operations at the integrated oil and petrochemical facility by the third quarter of 2014. As part of the expansion, the firms will consider increasing the capacity of the existing ethane cracker to take in an additional 30 million cubic feet per day of feedstock ethane. The venture will also consider building a new aromatics complex using around three million tonnes per year of naphtha as feedstock, and will also look at constructing various petrochemical units, the company said in April. Investment costs could total $3.1 billion to $5.1 billion with funds to come from the ventures two parents and borrowings from a group of banks.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read